PT - JOURNAL ARTICLE AU - Qian, Shuang AU - Ugurlu, Devran AU - Fairweather, Elliot AU - Strocchi, Marina AU - Toso, Laura Dal AU - Deng, Yu AU - Plank, Gernot AU - Vigmond, Edward AU - Razavi, Reza AU - Young, Alistair AU - Lamata, Pablo AU - Bishop, Martin AU - Niederer, Steven TI - Developing Cardiac Digital Twins at Scale: Insights from Personalised Myocardial Conduction Velocity AID - 10.1101/2023.12.05.23299435 DP - 2024 Jan 01 TA - medRxiv PG - 2023.12.05.23299435 4099 - http://medrxiv.org/content/early/2024/01/05/2023.12.05.23299435.short 4100 - http://medrxiv.org/content/early/2024/01/05/2023.12.05.23299435.full AB - Large-cohort studies using cardiovascular imaging and diagnostic datasets have assessed cardiac anatomy, function, and outcomes, but typically do not reveal underlying biological mechanisms. Cardiac digital twins (CDTs) provide personalized physics- and physiology-constrained in-silico representations, enabling inference of multi-scale properties tied to these mechanisms.We constructed 3464 anatomically-accurate CDTs using cardiac magnetic resonance images from UK biobank and personalised their myocardial conduction velocities (CVs) from electrocardiograms (ECG), through an automated framework.We found well-known sex-specific differences in QRS duration were fully explained by myocardial anatomy, as CV remained consistent across sexes. Conversely, significant associations of CV with ageing and increased BMI suggest myocardial tissue remodelling. Novel associations were observed with left ventricular ejection fraction and mental-health phenotypes, through a phenome-wide association study, and CV was also linked with adverse clinical outcomes.Our study highlights the utility of population-based CDTs in assessing intersubject variability and uncovering strong links with mental health.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project is supported by the Wellcome Trust and EPSRC Centre for Medical Engineering (WT203148/Z/16/Z). S.N is also supported by NIH R01-HL152256, ERC PREDICT-HF 453 (864055), BHF (RG/20/4/34803), EPSRC (EP/X012603/1, EP/P01268X/1) and by the Technology Missions Fund under the EPSRC Grant EP/X03870X/1 & The Alan Turing Institute. M.B acknowledges BHF Project Grants PG/22/11159 and PG/22/10871.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The imaging data and non-imaging participant phenotypes and clinical outcomes are available from UK Biobank via a standard application procedure at http://www.ukbiobank.ac.uk/register-apply.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe imaging data and non-imaging participant phenotypes and clinical outcomes are available from UK Biobank via a standard application procedure at http://www.ukbiobank.ac.uk/register-apply. The model generation are performed using open-sourced software: OpenCarp, available at https://opencarp.org/.